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Abstract
Background—Adequately-powered studies directly comparing hard clinical outcomes of 
darbepoetin alfa (DPO) versus epoetin alfa (EPO) in patients undergoing dialysis are lacking.
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Study Design—Observational, registry-based, retrospective cohort study; we mimicked a 
cluster-randomized trial by comparing mortality and cardiovascular events in US patients 
initiating hemodialysis in facilities (almost) exclusively using DPO versus EPO.
Setting & Participants—Non-chain US hemodialysis facilities; each facility switching from 
EPO to DPO (2003–2010) was matched on location, profit status, and facility type with one EPO 
facility. Patients subsequently initiating hemodialysis in these facilities were assigned their 
facility-level exposure.
Intervention—DPO versus EPO.
Outcomes—All-cause mortality, cardiovascular mortality; composite of cardiovascular death, 
non-fatal myocardial infarction, and non-fatal stroke.
Measurements—Unadjusted and adjusted HRs from Cox proportional hazards regression 
models.
Results—Of 508 dialysis facilities that switched to DPO, 492 were matched with a similar EPO 
facility; 19,932 (DPO: 9465 [47.5%]; EPO: 10,467 [52.5%]) incident hemodialysis patients were 
followed up for 21,918 person-years during which 5550 deaths occurred. Almost all baseline 
characteristics were tightly balanced. The demographics-adjusted mortality HR for DPO (versus 
EPO) was 1.06 (95% CI, 1.00–1.13) and remained materially unchanged after adjustment for all 
other baseline characteristics (HR, 1.05; 95% CI, 0.99–1.12). Cardiovascular mortality did not 
differ between groups (HR, 1.05; 95% CI, 0.94–1.16). Non-fatal outcomes were evaluated among 
9455 patients with fee-for-service Medicare: 4542 (48.0%) in DPO and 4913 (52.0%) in EPO 
facilities. Over 10,427 and 10,335 person-years, 246 strokes and 370 MIs were recorded, 
respectively. We found no differences in adjusted stroke or MI rates, or their composite with 
cardiovascular death (HR, 1.10; 95% CI, 0.96–1.25).
Limitations—Non-random treatment assignment, potential residual confounding.
Conclusions—In incident hemodialysis patients, mortality and cardiovascular event rates did 
not differ among patients treated at facilities predominantly using DPO versus EPO.
Keywords
Mortality; Cardiovascular; Safety; Myocardial Infarction; Stroke; hemodialysis; darbepoetin alfa 
(DPO); epoetin alfa (EPO); recombinant erythropoietin; erythropoiesis-stimulating agent (ESA); 
renal replacement therapy (RRT)
Anemia is a common complication of chronic kidney disease (CKD) that affects the vast 
majority of patients with end-stage renal disease (ESRD) receiving hemodialysis. Treatment 
with an erythropoiesis-stimulating agent (ESA), often in conjunction with intravenous iron 
supplementation, constitutes the standard of care for correction of anemia. In April 2013, 
85.6% of US hemodialysis patients were estimated to have received ESA treatment.1 In the 
United States, epoetin alfa (EPO) is the predominant ESA used by large dialysis chains, 
whereas the more recently approved longer-acting ESA, darbepoetin alfa (DPO), is mainly 
used in independent and hospital-based dialysis units.2 In 2011, 94.1% of ESA-treated US 
hemodialysis patients used EPO and 5.9% used DPO.3 By contrast, DPO is much more 
commonly used in other countries. For example, in 2011 DPO was used by 65.1% of 
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hemodialysis patients in Canada, 55.2% in France, and 48.2% in Japan.3 While the ability of 
DPO to raise and maintain hemoglobin concentrations is similar to that of EPO,4, 5 
sufficiently powered studies on the comparative safety of DPO versus EPO are lacking.
The recent case of another ESA, peginesatide, which was recalled less than a year after 
approval by the US Food and Drug Administration due to high rates of death and 
cardiovascular events not detected during its relatively large phase III program,6, 7 casts 
doubt on the validity of a “class effect” assumption of comparable safety among other ESAs. 
A recent meta-analysis of randomized trials that assigned patients with CKD to DPO versus 
EPO found no difference in mortality, but the upper bound of the 95% confidence interval 
(CI) exceeded a doubling in risk (odds ratio, 1.33; 95% CI, 0.88–2.01).8 A recent network 
meta-analysis that examined additional (non-death) outcomes, but included fewer trials, 
concluded that any comparisons among ESAs of cardiovascular outcomes such as MI or 
stroke were limited by high uncertainty.9 Hence, we sought to compare the safety of DPO 
and EPO in a large cohort of typical patients with ESRD initiating maintenance 
hemodialysis. In this study, we exploited the natural experiment that occurs when facilities 
make a formulary decision to provide one or the other drug to all or nearly all of its patients.
Methods
Study Rationale
Dialysis facilities contract their medications through pre-specified formularies with a facility 
typically administrating either DPO or EPO, but rarely both. We considered the choice 
between DPO and EPO as potentially random relative to patient characteristics because such 
decisions, particularly at the introduction of a new drug, are primarily based on contracts 
with drug suppliers. Since it is not expected that patients choose a facility based on whether 
it uses DPO or EPO, we may have the opportunity to exploit these facility level decisions as 
a natural experiment. Specifically, we used administrative data to mimic a cluster-
randomized design, with clustering based on facility by assigning facilities and their incident 
hemodialysis patients to a treatment arm based on the practice pattern of their facility. We 
then matched facility pairs for analytic purposes.
Study Population: Patient Selection, Exposure Assignment, and Follow-up
From the US Renal Data System (USRDS), the national registry of persons with ESRD, we 
identified from billing codes to Medicare all ESA administrations in 2003–2010. We then 
defined the proportion of ESA administrations that were for DPO versus for EPO in each 
hemodialysis facility and calendar month. For each facility, we termed a month a DPO 
facility-month if ≥95% of administered ESAs in that facility and month were DPO; 
correspondingly, if ≥95% of administrations were EPO, we considered it an EPO facility-
month. All other facility-months were categorized as “mixed”. We restricted our study to 
independent and hospital-based facilities, as it had previously been shown (and confirmed 
here) that large dialysis chains almost exclusively used EPO.2 Beginning with the approval 
of DPO by the US Food and Drug Administration for the US market in 2001, we identified 
all facility-level switches from EPO to DPO. Among the facilities that almost exclusively 
administered EPO in the same month and year, we randomly selected one facility matched 
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on geographic region (census division), profit status (for-profit vs. not-for-profit), and 
facility type (free-standing vs. hospital-based) as reported in the USRDS. This algorithm 
was applied to all observed facility switches from EPO to DPO.
From the first day of the matching month onwards, we identified all patients regardless of 
their insurance status who initiated hemodialysis in a DPO facility and its matched EPO 
facility (inception cohort design). If a facility switched back from predominant DPO to 
predominant EPO use or its matching EPO facility switched to DPO, both matched facilities 
were no longer eligible to contribute new incident patients to the study. Patients initiating 
hemodialysis in a DPO facility were assigned DPO and patients initiating hemodialysis in an 
EPO facility were assigned EPO as their respective exposures, regardless of whether they 
actually received DPO, EPO, or no ESA. We used this cohort to study mortality outcomes, 
which are recorded regardless of payor. Patients were censored at end of available data 
(December 31, 2010), upon switching to peritoneal dialysis, upon receipt of a kidney 
transplant, when switching to another hemodialysis facility, or when their facility or its 
match switched to predominant use of the respective other ESA, or was acquired by a large 
dialysis chain.
For analyses on non-fatal outcomes, we relied on claims-based data. Therefore, we restricted 
the cohort to patients who survived 90 days after the initiation of dialysis and who had 
Medicare Parts A+B as their primary payor on that day. In the US, most patients with ESRD 
are eligible for Medicare benefits after a 90-day waiting period from the date of ESRD 
incidence certified in the Medical Evidence Report (form CMS-2728). Patients were 
followed from day 91 after initiation of hemodialysis until censoring for the reasons listed 
above, as well as death (for nonfatal outcomes), or loss of Medicare Parts A+B coverage.
To examine the validity of using facility preference as the proxy for true exposure over time, 
we plotted for each month of follow-up the percentages of actual ESA received for each 
exposure group among prevalent and incident patients who had Medicare Parts A+B.
Patient Characteristics
From the USRDS patient file, we ascertained patients’ age, sex, race (white, black, Asian, 
Native American/Pacific Islander, other), ethnicity (Hispanic vs. non-Hispanic), and whether 
they were covered by Medicaid (a health insurance program for low-income patients). From 
the Medical Evidence Report, we ascertained the reported presence of several comorbidities 
(diabetes, hypertension, arteriosclerotic heart disease, heart failure, peripheral artery disease, 
cerebrovascular disease, chronic obstructive lung disease, cancer, inability to ambulate or 
transfer, tobacco use, drug use, alcohol use) as well as body mass index, serum hemoglobin 
and serum albumin concentrations, and the reported estimated glomerular filtration rate at 
initiation of dialysis. We also noted whether a patient was reported in the Medical Evidence 
Report to have received ESAs prior to initiation of dialysis.
Outcomes
Mortality from any cause and cardiovascular mortality were ascertained from the death file 
in the USRDS, which collates pertinent information from several federal sources. Non-fatal 
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outcomes of interest were ascertained from International Classification of Diseases, 9th 
Revision, (ICD-9) diagnosis codes (primary diagnosis field) from inpatient Medicare claims 
using validated algorithms and included stroke (ICD-9: 430, 431, 432.x, 433.x1, 434.x1, 
436, 437.1), myocardial infarction (MI; ICD-9: 410.x1), as well as a composite of stroke, 
MI, and cardiovascular mortality.10
Statistical Analysis
We first tabulated the characteristics of the matched DPO and EPO facilities. We then 
tabulated the characteristics of all enrolled incident hemodialysis patients by whether they 
dialyzed in a DPO versus an EPO facility. Groups were compared using standardized 
difference, with <10% indicating good balance.11 We examined cumulative incidence plots 
for all outcomes for any differences in event rates or censoring events. We used Cox 
proportional hazards regression stratified on facility pair to estimate unadjusted hazard ratios 
(HRs) and corresponding 95% CIs. Schoenfeld residual plots were examined to identify any 
violations of the proportionality assumption. Since a few characteristics were slightly 
unbalanced between groups, we also fit demographics-adjusted models and models that 
included all reported comorbidities and biometric/laboratory characteristics. Missing data 
were addressed using the MICE (Multivariate Imputation by Chained Equations) package in 
R statistical software (R Foundation for Statistical Computing).12 We also conducted a set of 
analyses that were restricted to patients who were reported, per Medical Evidence Report, to 
have not received any ESA prior to ESRD (ESA naïve). We also inspected cumulative 
incident plots of all outcomes and censoring events and confirmed in formal competing risk 
analyses that reported results were unaffected by potential informative censoring (data not 
shown).
We conducted statistical analyses using SAS software, version 9.3 (SAS Instiute Inc) and R 
statistical software. The Stanford University School of Medicine Institutional Review Board 
approved the study.
Results
From 2003 through 2010, among 5872 US hemodialysis facilities, 2067 (35.2%) were not 
part of a chain and of those, 508 (24.6%) facilities switched from EPO to DPO (see Figure 
S1, available as online supplementary material, for the timing of these switches). Of those, 
we matched on center type, profit status, and geographic region 492 units (96.9%) with one 
unit each that had continued to use EPO in the same month and year (Table 1). After the 
index date and prior to censoring of the matched facility-pair, 19,932 patients initiated 
hemodialysis in these centers, 9,465 (47.5%) in DPO and 10,467 (52.5%) in EPO facilities 
(Figure 1), and were followed up for a total of 21,848 person-years. We locked the 
analytical dataset on October 18, 2013, prior to examining any outcomes and conducted 
power calculations for fatal and nonfatal endpoints, which demonstrated excellent power for 
the detection of even small effect sizes (Figure S2). For example, we had 97.8% (53.0%) 
power to detect a 10% (5%) increase in mortality.
Patient characteristics were similar among patients initiating hemodialysis in DPO vs. EPO 
facilities with the exception of race and ethnicity (Table 2): DPO facilities had fewer 
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Hispanic and Asian patients, and they also had slightly lower reported serum albumin 
concentrations. Patient-level separation of ESA exposure during follow-up, assessed from 
monthly-prevalent patients with Medicare coverage in these units, was excellent as shown in 
Figure 2. Furthermore, use of intravenous iron and achieved hemoglobin concentrations 
during follow up were very similar (Figures S3 and S4). Cumulative incidence plots did not 
indicate any differential censoring between the exposure groups and competing risk analyses 
yielded essentially identical results (data not shown).
During follow-up, 5550 deaths and 2037 cardiovascular deaths occurred for incidence rates 
of 253.2 and 92.9 per 1000 person-years, respectively (Table 3). Compared with patients 
who initiated dialysis in EPO facilities, patients in DPO facilities had 12% higher mortality 
(HR, 1.12; 95% CI, 1.06–1.20), but survival did not differ significantly between groups after 
adjustment for demographic characteristics (HR, 1.06; 95% CI, 1.00–1.13) or adjustment for 
all recorded factors (HR, 1.05; 95% CI, 0.99–1.12). Results for cardiovascular mortality 
were very similar, albeit with wider confidence limits (adjusted HR, 1.05; 95% CI, 0.94–
1.16; Table 3).
For analyses of non-fatal endpoints that were ascertained from medical claims, we identified 
9455 incident hemodialysis patients who were alive and covered by Medicare Parts A+B at 
90 days after the reported ESRD date; 4542 (48.0%) in DPO and 4913 (52.0%) in EPO 
facilities. The few imbalances between groups mirrored those of the larger cohort described 
above (Table S1). Over 10,427 and 10,335 person-years, 246 strokes and 370 MIs were 
recorded for incidence rates of 23.6 and 35.8 per 1000 person-years, respectively. We found 
no differences in adjusted stroke or MI rates, or their composite with cardiovascular death 
(HR, 1.10; 95% CI, 0.96–1.25) (Table 2).
In subgroup analyses of 11,553 patients who were reported to have been ESA-naïve at 
hemodialysis initiation, results for mortality (HR, 1.01; 95% CI, 0.92–1.10) and 
cardiovascular mortality (HR, 1.01; 95% CI, 0.87–1.17) were consistent with those obtained 
from the full cohort (Table S3). Similarly, in the subset of 5474 patients who were ESA 
naïve, alive and with Medicare coverage at day 90, non-fatal stroke, non-fatal MI, and their 
composite with cardiovascular mortality were not associated with DPO vs. EPO in adjusted 
analyses (HR, 1.13; 95% CI, 0.95–1.35).
Discussion
Darbepoetin alfa and EPO are two medications from the ESA class that are commonly used 
for the treatment of anemia in individuals receiving dialysis and in other settings. While 
similar in their ability to raise and maintain hemoglobin concentrations in short-term 
studies,4, 5, 13 longer-term clinical trials that could detect meaningful differences in adverse 
outcomes are absent. In a meta-analysis of head-to-head trials of DPO versus EPO, no 
significant difference in mortality was found, but numbers were small, follow-up short, and 
CIs wide and compatible with sizeable excess mortality in patients randomized to DPO.8 In 
this study, we leveraged the apparent natural experiment that occurred when facilities 
switched from EPO to DPO to compare outcomes in patients on hemodialysis. Importantly, 
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we detected no significant differences in death, cardiovascular death, or non-fatal 
cardiovascular events among patients treated in DPO versus EPO facilities.
We focused on cardiovascular and mortality end-points since previous randomized trials of 
either DPO or EPO that either compared higher versus lower hemoglobin targets or active 
ESA versus placebo had identified mostly cardiovascular safety signals. However, the 
specific safety signals differed across studies, which raises the possibility that the type of 
adverse outcome depended on the specific ESA used.14 As already stated in our meta-
analysis,15 there are well-documented biologic differences between DPO and EPO, with the 
most important difference for the clinician being the prolonged half-life and increased 
biological activity for DPO in comparison to EPO.16-19 While the therapeutic aim of ESA 
treatment is to increase or maintain hemoglobin concentrations in patients with anemia, 
other effects on additional tissues and organs have been identified, including the brain, heart, 
uterus, and kidney.20, 21 Erythropoietin may possess pleiotropic properties, stimulating 
proliferation, chemotaxis, and angiogenesis while downregulating apoptosis.22, 23 It appears 
to be an important regulator of vascular repair and may also be involved in neoangiogenesis. 
Both DPO and EPO have been shown to enhance mobilization of bone-marrow derived 
endothelial-progenitor cells in humans24, 25; these cells play important roles in vascular 
repair and endothelial regeneration in ischemia-reperfusion injury.21, 26, 27 These non-
hematopoietic effects of ESAs, however, may differ from and be disproportional to their 
relative effectiveness in inducing hematopoiesis. Another derivative of erythropoietin, 
carbamylated erythropoietin, has been shown to offer similar cardioprotection as epoetin 
alfa in an animal model, while not exerting an effect on hematocrit.28, 29 This experimental 
research then raises the important question that we tried to address in this study, namely 
whether off-target, non-hematopetic, effects may differ between DPO and EPO.
Certain limitations of our study require consideration. Our comparison of DPO and EPO 
was not randomized and therefore residual confounding remains possible. However, we used 
an intuitive quasi-experimental approach that mimicked a cluster-randomized trial in which 
facilities rather than individual patients are randomized to receiving one treatment or 
another. While the current study was not randomized, treatment with DPO versus EPO was 
presumably determined by formulary decisions on the facility level, and was found to be 
mostly independent of patient characteristics. Indeed, after matching facilities by specific 
criteria such as location, type, and profit status, patients were similar between facilities that 
had switched to DPO and EPO facilities. Achieved hemoglobin concentrations and use of 
intravenous iron over the full range of follow-up were very similar between the two groups 
corroborating that, indeed, the only difference in anemia management was the choice of 
ESA, but not any presumed or explicit hemoglobin target or iron use strategy. However, we 
cannot firmly establish from data available to us that facility switches were, indeed, a 
consequence of facility-wide formulary decisions; alternatively, these switches could have 
been caused by clinician preferences, nursing workloads, or concerns about EPO safety, and 
could have been correlated with other facility practices (e.g., dialysis prescriptions, infection 
control protocols) that may have confounded the estimated associations.
A second limitation comes from the fact that DPO is not widely used in the United States, 
which required that we restrict our analyses to non-chain freestanding and hospital-based 
Winkelmayer et al. Page 7













facilities. Whether our results generalize to other healthcare settings such as chain dialysis 
facilities or to other countries remains unknown. While the ensuing sample size was 
relatively modest for a national registry analysis, it was more than 20-times the sample size 
of all randomized trials of DPO vs. EPO combined (and whose endpoints were hemoglobin 
control), which enabled us to study important outcomes with excellent power. We were also 
able to demonstrate that there was very little exposure misclassification, with an average 
98.9% of ESA recipients in DPO facilities receiving DPO and 99.7% of ESA recipients in 
EPO facilities receiving EPO throughout follow-up. Thus, statistical power was not diluted 
by treatment cross-overs. However, not all patients received ESA and not all patients who 
did received it throughout follow-up, and so a per-protocol analysis of patients treated with 
ESA would not possess this inherent bias towards the null. Unfortunately, the specific 
question asked in our study is not addressable by employing causal methods (e.g., marginal 
structural models) developed to address time-dependent confounding (and our dataset would 
not have provided the highly-granular data required to support the use of such methods). Our 
sensitivity analyses of presumably ESA-naïve patients used information provided on the 
Medical Evidence Report, which has been shown to substantially misclassify pre-ESRD use 
of ESAs in two validation studies.30, 31 Finally, we were unable to study other ESAs, 
including epoetin beta, epoetin delta, epoetin omega, biosimilar epoetins, or the long-acting 
methoxy polyethylene glycol–epoetin beta, all of which are available in other countries, but 
not currently used in the United States due to patent restrictions.
We conclude that DPO and EPO possess roughly similar safety profiles, at least within the 
hemodialysis setting, with regard to cardiovascular and mortality outcomes, although small 
excess risks from DPO cannot be ruled out.
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Figure 1. Numbers of Facilities Matched and Incident Patients Enrolled
Note: DPO – darbepoetin alfa; EPO – epoetin alfa; ESRD – end-stage renal disease. 
Whether a patient was ESA naïve was determined from the Medical Evidence Report.
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Figure 2. Actual Treatment Received Among Patients in Darbepoetin Alfa versus Epoetin Alfa 
Facilities, by Month of Follow-up
Upper panels show the percentages of prevalent hemodialysis patients with Medicare Parts 
A+B who received darbepoetin alfa (DPO) versus epoetin alfa (EPO) versus both in each 
calendar month; Lower panels show the percentages of incident hemodialysis patients with 
Medicare Parts A+B who received darbepoetin alfa versus epoetin alfa versus both in each 
calendar month (corresponds to cohort studies for nonfatal outcomes). Left panels are 
darbepoetin alfa facilities, right panels are epoetin alfa facilities. MPAB – Medicare primary 
payor, Parts A+B.
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Table 1
Characteristics of DPO and Matched EPO Facilities
Variable DPO (n=492) EPO (n=492)
Facility Type
   Free-standing 173 (35.2) 173 (35.2)
   Hospital 319 (64.8) 319 (64.8)
Profit-status
   Not for profit 359 (73.0) 359 (73.0)
   For profit 133 (27.0) 133 (27.0)
Facility size
   0–49 patients 240 (48.8) 260 (52.8)
   50–99 patients 148 (30.1) 133 (27.0)
   ≥100 patients 104 (21.1) 99 (20.1)
Region
   Northwest 102 (20.7) 102 (20.7)
   Midwest 215 (43.7) 215 (43.7)
   South 106 (21.5) 106 (21.5)
   West 69 (14.0) 69 (14.0)
Note: Values are given as number (percentage). From among 508 facilities that switched from EPO to DPO between 2003 and 2010, we hard-
matched one dialysis unit that remained with EPO on facility type (hospital based vs. independent), for-profit status, and geographic region in the 
month and year of the switching event. We were able to match 492 (96.9%) of facilities that switched to DPO.
DPO, darbepoetin alfa; EPO, epoetin alfa
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